Vedanta Biosciences Announces Preclinical Data on Microbiome-Derived Immuno-Oncology Candidate
Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, announced preclinical data for VE800, the Company’s orally-administered, live biotherapeutic product candidate in […]